Abstract: Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.
From the Henry Ford Hospital, Detroit, MI.
Correspondence to: Jose A. Vazquez, MD, Henry Ford Hospital, 2799 W Grand Blvd, CFP 202, Detroit, MI 48202. E-mail: email@example.com.
J Vazquez is with the speakers’ bureaus of Pfizer, Astellas, Forest, and Merck. He has received grants from Merck and Astellas. H Zainah has no funding or conflicts of interest to disclose.
The authors have no funding to disclose.